Global Spinal Muscular Atrophy (SMA) Treatment Markets, 2014-2017 & 2018-2025: The Market is Led by Biogen's Spinraza - The Only Approved Commercialized Treatment

Thursday, 25. April 2019 10:37

Dublin, April 25, 2019 (GLOBE NEWSWIRE) -- The "Spinal Muscular Atrophy (SMA) Treatment Market Size, Share & Trends Analysis Report By Route of Administration (Oral, Intrathecal), By Treatment (Gene Therapy, Drug), By Disease Type, And Segment Forecasts, 2018 - 2025" report has been added to ResearchAndMarkets.com's offering.

The global spinal muscular atrophy (SMA) treatment market size is expected to reach USD 3.9 billion by 2025

It is estimated to register a CAGR of 12.9% during the forecast period. Due to the rare nature and complexity of these diseases, scientific knowledge pertaining to them is scarce. However, there are various initiatives undertaken to increase awareness regarding rare diseases and to support SMA communities. This is anticipated to boost the market development over the coming years.

Various SMA communities and companies have collaborated for developing disease treatment therapy. For example, RG7916, which is an investigational therapy being developed by Roche in collaboration with SMA Foundation and PTC Therapeutics. Thus, heavy investments in R&D by major companies are also projected to contribute toward the growth of this market. CureSMA, SMA Foundation, and SMA Europe are some of the organizations actively supporting R&D pertaining to SMA.

CureSMA provided funding to a research project to Biogen and Ionis Pharmaceuticals, Inc. for developing Spinraza, which received U.S. FDA approval in 2016. This organization has invested nearly USD 70 million in the research pertaining to SMA, which also included a planned investment of USD 5 million in the coming years.

Further key findings from the study suggest:

  • The global spinal muscular atrophy treatment market is projected to expand at a CAGR of 12.9% over the forecast period
  • Based on disease type, type 1 accounted for the largest revenue share owing to rising incidence of type 1 SMA
  • By treatment, the drug segment accounted for the largest revenue share in 2017
  • North America will retain its lead as the largest regional market; however Asia Pacific is anticipated to register the fastest CAGR over the forecast period
  • The market is presently led by Biogen Inc. Biogen's Spinraza is the only approved commercialized treatment for SMA, owing to which market is not competitive. However, this trend is expected to change after the commercialization of other treatment therapies post 2020

Key Topics Covered:

Chapter 1 Research Methodology
1.1 Information Procurement
1.2 Data Analysis

Chapter 2 Executive Summary
2.1 Market Snapshot

Chapter 3 Spinal Muscular Atrophy Treatment Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.2 Market Driver Analysis
3.2.1 Rising importance of rare diseases
3.2.2 Increasing initiatives for creating awareness of SMA
3.2.3 Growing research initiatives by market players for developing treatment for SMA
3.3 Market Restraint Analysis
3.3.1 Limited access to treatment of SMA
3.4 Key Opportunities Prioritized
3.5 Spinal Muscular Atrophy Treatment Market - SWOT Analysis, by Factor (Political & legal, Economic, and Technological)
3.6 Industry Analysis - Porter's

Chapter 4 Spinal Muscular Atrophy Treatment Market: Disease Type Estimates & Trend Analysis
4.1 Spinal Muscular Atrophy Treatment Market: Disease Type Movement Analysis
4.2 Type 1
4.3 Type 2
4.4 Type 3
4.5 Type 4

Chapter 5 Spinal Muscular Atrophy Treatment Market: Treatment Estimates & Trend Analysis
5.1 Spinal Muscular Atrophy Treatment Market: Treatment Movement Analysis
5.2 Gene Therapy
5.3 Drug
5.3.2 Spinraza
5.3.3 RG6083 (Olesoxime)
5.3.4 RG7916

Chapter 6 Spinal Muscular Atrophy Treatment Market: Route of Administration Estimates & Trend Analysis
6.1 Spinal Muscular Atrophy Treatment Market: Route of Administration Movement Analysis
6.2 Oral
6.3 Intrathecal

Chapter 7 Spinal Muscular Atrophy Treatment Market: Regional Estimates & Trend Analysis by Disease Type, Treatment, and Route of Administration

Chapter 8 Competitive Landscape

  • Biogen
  • Ionis Pharmaceuticals, Inc.
  • F. Hoffmann - La Roche Ltd
  • Avexis, Inc.
  • Novartis AG
  • Cytokinetics, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/6vapfn

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs 

22157.jpg

Related Links: 
Author:
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.